151 related articles for article (PubMed ID: 30783078)
1. Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations.
Peterson JF; Rowsey RA; Marcou CA; Pearce KE; Williamson CM; Frederick LA; Greipp PT; Ketterling RP; Kumar S; Viswanatha DS; Polley MY; Fink JM; Reichard KK; Van Dyke DL; Baughn LB
Blood Cancer J; 2019 Feb; 9(3):20. PubMed ID: 30783078
[No Abstract] [Full Text] [Related]
2. Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma.
Sawyer JR; Tian E; Shaughnessy JD; Epstein J; Swanson CM; Stangeby C; Hale CL; Parr L; Lynn M; Sammartino G; Lukacs JL; Stein C; Bailey C; Zangari M; Davies FE; Van Rhee F; Barlogie B; Morgan GJ
Leukemia; 2017 Mar; 31(3):637-644. PubMed ID: 27694925
[TBL] [Abstract][Full Text] [Related]
3. Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience.
Carballo-Zarate AA; Medeiros LJ; Fang L; Shah JJ; Weber DM; Thomas SK; Manasanch EE; Hao S; Shen Q; Orlowski RZ; Lin P; Lu X
Mod Pathol; 2017 Jun; 30(6):843-853. PubMed ID: 28281554
[TBL] [Abstract][Full Text] [Related]
4. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma.
Thakurta A; Ortiz M; Blecua P; Towfic F; Corre J; Serbina NV; Flynt E; Yu Z; Yang Z; Palumbo A; Dimopoulos MA; Gutierrez NC; Goldschmidt H; Sonneveld P; Avet-Loiseau H
Blood; 2019 Mar; 133(11):1217-1221. PubMed ID: 30692124
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival.
Chin M; Sive JI; Allen C; Roddie C; Chavda SJ; Smith D; Blombery P; Jones K; Ryland GL; Popat R; Rismani A; D'Sa S; Rabin N; Gale RE; Yong KL
Blood Cancer J; 2017 Sep; 7(9):e610. PubMed ID: 29016571
[No Abstract] [Full Text] [Related]
6. p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide.
Chen MH; Qi CX; Saha MN; Chang H
Am J Clin Pathol; 2012 Feb; 137(2):208-12. PubMed ID: 22261445
[TBL] [Abstract][Full Text] [Related]
7. Monosomal karyotype routinely defines a poor prognosis subgroup in acute myeloid leukemia and is frequently associated with TP53 deletion.
Gaillard JB; Chiesa J; Reboul D; Arnaud A; Brun S; Donadio D; Exbrayat C; Wickenhauser S; Bourquard P; Jourdan E; Lavabre-Bertrand T
Leuk Lymphoma; 2012 Feb; 53(2):336-7. PubMed ID: 21823831
[No Abstract] [Full Text] [Related]
8. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy.
Boyd KD; Ross FM; Tapper WJ; Chiecchio L; Dagrada G; Konn ZJ; Gonzalez D; Walker BA; Hockley SL; Wardell CP; Gregory WM; Child JA; Jackson GH; Davies FE; Morgan GJ;
Genes Chromosomes Cancer; 2011 Oct; 50(10):765-74. PubMed ID: 21961181
[TBL] [Abstract][Full Text] [Related]
9. The frequency and clinical outcome of mono-hit and multi-hit TP53 aberrations in newly diagnosed multiple myeloma.
Sreedharanunni S; Singla S; Balakrishnan A; Singh A; Jamwal M; Singh N; Singh C; Jandial A; Lad D; Sharma P; Sachdeva MUS; Malhotra P; Das R
Pathology; 2024 Jun; 56(4):556-564. PubMed ID: 38413253
[TBL] [Abstract][Full Text] [Related]
10. [Investigation of the molecular changes in patients with multiple myeloma by fluorescence in situ hybridization].
Yang RF; Li CM; Chen LJ; Qiu HR; Yang H; Liu P; Xu JR; Li JY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Oct; 27(5):567-70. PubMed ID: 20931539
[TBL] [Abstract][Full Text] [Related]
11. Cytogenetic and fluorescence in situ hybridization studies in 60 patients with multiple myeloma and plasma cell leukemia.
Lloveras E; Granada I; Zamora L; Espinet B; Florensa L; Besses C; Xandri M; Pérez-Vila ME; Millà F; Woessner S; Solé F
Cancer Genet Cytogenet; 2004 Jan; 148(1):71-6. PubMed ID: 14697644
[TBL] [Abstract][Full Text] [Related]
12. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma.
Lodé L; Eveillard M; Trichet V; Soussi T; Wuillème S; Richebourg S; Magrangeas F; Ifrah N; Campion L; Traullé C; Guilhot F; Caillot D; Marit G; Mathiot C; Facon T; Attal M; Harousseau JL; Moreau P; Minvielle S; Avet-Loiseau H
Haematologica; 2010 Nov; 95(11):1973-6. PubMed ID: 20634494
[TBL] [Abstract][Full Text] [Related]
13. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia.
Rasillo A; Tabernero MD; Sánchez ML; Pérez de Andrés M; Martín Ayuso M; Hernández J; Moro MJ; Fernández-Calvo J; Sayagués JM; Bortoluci A; San Miguel JF; Orfao A
Cancer; 2003 Feb; 97(3):601-9. PubMed ID: 12548602
[TBL] [Abstract][Full Text] [Related]
14. Hyperhaploid plasma cell myeloma.
Hoctor VT; Campbell LJ
Cancer Genet; 2012; 205(7-8):414-8. PubMed ID: 22868003
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Implications of Monosomies in Patients With Multiple Myeloma.
Shin SY; Eom HS; Sohn JY; Lee H; Park B; Joo J; Jang JH; Lee MN; Kim JK; Kong SY
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):159-164.e2. PubMed ID: 28089441
[TBL] [Abstract][Full Text] [Related]
16. The level of deletion 17p and bi-allelic inactivation of
Thanendrarajan S; Tian E; Qu P; Mathur P; Schinke C; van Rhee F; Zangari M; Rasche L; Weinhold N; Alapat D; Bellamy W; Ashby C; Mattox S; Epstein J; Yaccoby S; Barlogie B; Hoering A; Bauer M; Walker BA; Davies FE; Morgan GJ
Haematologica; 2017 Sep; 102(9):e364-e367. PubMed ID: 28550191
[No Abstract] [Full Text] [Related]
17. Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%.
Mühlbacher V; Zenger M; Schnittger S; Weissmann S; Kunze F; Kohlmann A; Bellos F; Kern W; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2014 Jun; 53(6):524-36. PubMed ID: 24619868
[TBL] [Abstract][Full Text] [Related]
18. del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.
Corre J; Perrot A; Caillot D; Belhadj K; Hulin C; Leleu X; Mohty M; Facon T; Buisson L; Do Souto L; Lannes R; Dufrechou S; Prade N; Orsini-Piocelle F; Voillat L; Jaccard A; Karlin L; Macro M; Brechignac S; Dib M; Sanhes L; Fontan J; Clement-Filliatre L; Marolleau JP; Minvielle S; Moreau P; Avet-Loiseau H
Blood; 2021 Mar; 137(9):1192-1195. PubMed ID: 33080624
[TBL] [Abstract][Full Text] [Related]
19. Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma.
Chang H; Yeung J; Qi C; Xu W
Br J Haematol; 2007 Aug; 138(3):324-9. PubMed ID: 17555471
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of TP53 mutation in myeloma.
Chng WJ; Price-Troska T; Gonzalez-Paz N; Van Wier S; Jacobus S; Blood E; Henderson K; Oken M; Van Ness B; Greipp P; Rajkumar SV; Fonseca R
Leukemia; 2007 Mar; 21(3):582-4. PubMed ID: 17215851
[No Abstract] [Full Text] [Related]
[Next] [New Search]
